Tianjin Da Ren Tang Reports No New Developments in Subsidiary Bankruptcy

Tianjin Zhongxin Pharmaceutical Group Corp. Ltd. Class S ( (DE:2TZ) ) has shared an update.

Tianjin Pharmaceutical Da Ren Tang Group Corporation Limited has reported that there have been no material developments in the bankruptcy liquidation of its 55%-owned subsidiary, Tianjin Shin Poong Pharmaceutical Co., Ltd., since its previous monthly update in November 2025. The group stated that the proceedings are not expected to have a significant impact on its financial position at this time, and it will continue to monitor the case closely, maintain active communication with the court and the administrator, and provide further monthly updates in line with listing rules, while advising shareholders and potential investors to exercise caution when dealing in its shares.

More about Tianjin Zhongxin Pharmaceutical Group Corp. Ltd. Class S

Tianjin Pharmaceutical Da Ren Tang Group Corporation Limited, formerly known as Tianjin Zhong Xin Pharmaceutical Group Corporation Limited, is a China-incorporated pharmaceutical group engaged in the development, manufacture and sale of medicinal products through its subsidiaries, serving domestic and international healthcare markets.

Find detailed analytics on 2TZ stock on TipRanks’ Stock Analysis page.